arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

HERON THERAPEUTICS, INC. /DE/

HRTX
$0.29 ▼ -0.01 (-2.97%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
68 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

HERON THERAPEUTICS, INC. /DE/ faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $55.2M
Dividend Yield —
Revenue Growth 1.3% ↗
Op. Margin -5.4% ↗
ROIC -23.4% ↗
FCF / Share $-0.01 ↘
Trailing P/E —
Price / Book 8.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$37.67M
↑ +1.3% —
Net Income Profit after all expenses
$-8.11M
— 0.0% —
Operating Margin Operating profit as % of sales
-5.4%
↑ +60.5% 25th
FCF / Share Free cash flow per share
$-0.01
↑ +82.8% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
16
Returns ↓
5
Financial Health ↑
47
Cash Quality ↑
78

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 18 years · 68 quarters